Company
Headquarters: New Taipei City, Taiwan
TW$2.11 Billion
TWD as of Jan. 1, 2024
US$68.8 Million
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $622.07 B |
Vertex Pharmaceuticals Incorporated | $121.36 B |
Regeneron Pharmaceuticals, Inc. | $115.11 B |
CSL Limited | $95.75 B |
Marinomed Biotech AG | $75.67 B |
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
SyneuRx International (Taiwan) Corp. develops drugs for the treatment of unmet medical needs in central nervous system disorders in Taiwan. Its pipeline under clinical development includes SND11, which is in Phase IIb/III clinical trial for the treatment of adolescent schizophrenia; SND12 that is in Phase IIb/III clinical trial for therapy on refractory schizophrenia; and SND13, which is in Phase IIb/III clinical trial for the treatment of adult schizophrenia. The company is also developing SND14, which is in Phase IIb/III clinical trial to treat early dementia; SND51 that is in Phase II clinical trial for dementia and psychosis symptoms; SNG12, which is in Phase III clinical trial for the treatment of depression and suicidality; SNA1 that is in Phase II clinical trial to treat refractory depression; and SNB01, which is in Phase II clinical trial for the treatment of COVID-19. SyneuRx International (Taiwan) Corp. was founded in 2013 and is based in New Taipei City, Taiwan.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
SyneuRx International has the following listings and related stock indices.
Stock: TWSE: 6575 wb_incandescent